Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 38

Sort by

Sort Order Select

Journal Articles

Phase 1 study of CAR-37 T cells in patients with relapsed or refractory CD37 + lymphoid malignancies

Blood (2024) 144 (11): 1153–1167.

https://doi.org/10.1182/blood.2024024104

Published: 2024

Includes: Supplemental data

Journal Articles

Two years later: CD19 CAR-T going the distance

Eli P. Darnell, Matthew J. Frigault

Blood (2024) 143 (5): 379–380.

https://doi.org/10.1182/blood.2023022670

Published: 2024

Journal Articles

Itacitinib for the Prevention of Immune Effector Cell Therapy-Associated Cytokine Release Syndrome: Results from the Phase 2 Incb 39110-211 Placebo-Controlled Randomized Cohort

Matthew J. Frigault, Richard T Maziarz, Jae H. Park, Aleksandr Lazaryan, Nirav N. Shah, Jakub Svoboda, Lazaros J. Lekakis, Ran Reshef, Christine L Phillips, Lea M Burke, Jing Lei, Rodica Morariu-Zamfir, John F. DiPersio

Blood (2023) 142 (Supplement 1): 356.

https://doi.org/10.1182/blood-2023-180205

Published: 2023

Journal Articles

Real-World Tisagenlecleucel Outcomes in Richter-Transformed Chronic Lymphocytic Leukemia: A Center for International Blood & Marrow Transplant Research (CIBMTR) Analysis

Mazyar Shadman, Matthew J Frigault, Stephen Ronan Foley, Brian T. Hill, Grant Schofield, Caron Jacobson, Samantha M. Jaglowski, Frederick L. Locke, Daniel J. Landsburg, Ron Ram, Peter A Riedell, Gunjan L. Shah, Leslie L. Popplewell, Ranjan Tiwari, Stephen Lim, Harald Jakob Maier, Marta Majdan, Marcelo Pasquini

Blood (2023) 142 (Supplement 1): 3497.

https://doi.org/10.1182/blood-2023-180233

Published: 2023

Journal Articles

Phase 1 Study of CART-Ddbcma for the Treatment of Patients with Relapsed and/or Refractory Multiple Myeloma: Results from at Least 1-Year Follow-up in All Patients

Matthew J. Frigault, Jacalyn Rosenblatt, Binod Dhakal, Noopur S. Raje, Daniella Cook, Mahmoud Gaballa, Estelle Emmanuel-Alejandro, Danielle Nissen, Kamalika C Banerjee, Anand Rotte, Christopher R Heery, David Avigan, Andrzej J Jakubowiak, Michael R. Bishop

Blood (2023) 142 (Supplement 1): 1023.

https://doi.org/10.1182/blood-2023-189761

Published: 2023

Journal Articles

Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Secondary Central Nervous System Large B-Cell Lymphoma (SCNSL): A Multicenter Retrospective Analysis

Blood (2023) 142 (Supplement 1): 3088.

https://doi.org/10.1182/blood-2023-184345

Published: 2023

Journal Articles

Durable Efficacy and Manageable Safety in Patients Age ≥ 75 Years with Relapsed/Refractory Large B-Cell Lymphoma Treated with Tisagenlecleucel in the Real-World Setting

Daniel J. Landsburg, Michael Heim, Amy Moskop, Stephen Ronan Foley, Brian T. Hill, Grant Schofield, Caron Jacobson, Samantha M. Jaglowski, Frederick L. Locke, Ron Ram, Peter A Riedell, Gunjan L. Shah, Leslie L. Popplewell, Ranjan Tiwari, Stephen Lim, Harald Jakob Maier, Marta Majdan, Marcelo Pasquini, Matthew J Frigault

Blood (2023) 142 (Supplement 1): 3496.

https://doi.org/10.1182/blood-2023-179387

Published: 2023

Journal Articles

Trial-in-Progress: A Phase 1/2 Multi-Center Study of Onct-808, a ROR1-Specific CAR T, in Adult Patients with Relapsed/Refractory Aggressive B Cell Lymphoma

Michael L. Wang, Matthew J. Frigault, Salim Yazji, Yisrael Katz, James Robinson, James B. Breitmeyer, Matthew G. Mei, Caron A Jacobson

Blood (2023) 142 (Supplement 1): 4857.

https://doi.org/10.1182/blood-2023-180989

Published: 2023

Journal Articles

Use of Cilta-Cel CAR T Cells Following Previous Use of a BCMA-Directed CAR T-Cell Product in Heavily Treated Patients with Relapsed/Refractory Multiple Myeloma: A Single Institution Case Series

Narsis Attar, Diana Cirstea, Andrew R. Branagan, Andrew J. Yee, Matthew J. Frigault, Noopur Raje

Blood (2023) 142 (Supplement 1): 6924.

https://doi.org/10.1182/blood-2023-182212

Published: 2023

Journal Articles

Chemotherapy-induced reversal of ciltacabtagene autoleucel–associated movement and neurocognitive toxicity

Charlotte E. Graham, Won-Ho Lee, Hadley R. Wiggin, Valentina M. Supper, Mark B. Leick, Filippo Birocchi, Andrew J. Yee, Angelina Petrichenko, John Everett, Frederic D. Bushman, Hossein Sadrzadeh, Otto Rapalino, Daniel Chiu, Isabel Arrillaga-Romany, Marcela V. Maus, Matthew J. Frigault, Kathleen M. E. Gallagher

Blood (2023) 142 (14): 1248–1252.

https://doi.org/10.1182/blood.2023021429

Published: 2023

Includes: Supplemental data

Journal Articles

Neurologic toxicities following adoptive immunotherapy with BCMA-directed CAR T cells

Philipp Karschnia, Kevin C. Miller, Andrew J. Yee, Kai Rejeski, P. Connor Johnson, Noopur Raje, Matthew J. Frigault, Jorg Dietrich

Blood (2023) 142 (14): 1243–1248.

https://doi.org/10.1182/blood.2023020571

Published: 2023

Journal Articles

Clonal hematopoiesis of indeterminate potential and risk of death from COVID-19

Blood (2022) 140 (18): 1993–1997.

https://doi.org/10.1182/blood.2022018052

Published: 2022

Includes: Supplemental data

Journal Articles

Safety and efficacy of tisagenlecleucel in primary CNS lymphoma: a phase 1/2 clinical trial

Blood (2022) 139 (15): 2306–2315.

https://doi.org/10.1182/blood.2021014738

Published: 2022

Includes: Supplemental data

Journal Articles

Real-World Efficacy and Safety Outcomes for Patients with Relapsed or Refractory (R/R) Aggressive B-Cell Non-Hodgkin's Lymphoma (aBNHL) Treated with Commercial Tisagenlecleucel: Update from the Center for International Blood and Marrow Transplant Research (CIBMTR) Registry

Daniel J Landsburg, Matthew J. Frigault, Zhen-Huan Hu, Samantha Jaglowski, Frederick L. Locke, Christine Ho, Miguel-Angel Perales, Caron Jacobson, Brian T. Hill, Stephen Ronan Foley, Peter A. Riedell, Ranjan Tiwari, Aisha Masood, Stephen Lim, Marta Majdan, Marcelo C Pasquini, Cameron J. Turtle

Blood (2021) 138 (Supplement 1): 429.

https://doi.org/10.1182/blood-2021-146397

Published: 2021

Journal Articles

Rational Chemical and Genetic Modifications Enhance Avidity and Function of CD70-Directed CAR-T-Cells for Myeloid Leukemia

Mark B. Leick, Harrison Silva, Irene Scarfò, Rebecca Larson, Bryan D. Choi, Amanda A Bouffard, Kathleen M.E. Gallagher, Andrea Schmidts, Stefanie R. Bailey, Michael C. Kann, Max Jan, Marc Wehrli, Korneel Grauwet, Matthew J. Frigault, Marcela V. Maus

Blood (2021) 138 (Supplement 1): 405.

https://doi.org/10.1182/blood-2021-150596

Published: 2021

Journal Articles

A Phase II Trial of Anakinra for the Prevention of CAR-T Cell Mediated Neurotoxicity

Matthew J. Frigault, Kathleen M.E. Gallagher, Marc Wehrli, Betsy Valles, Keagan Casey, Kevin Lindell, Michael Trailor, Hana Cho, Jami L. Brown, Nora K. Horick, Justin Chou, Rhine R. Shen, Simone Filosto, Adrian Bot, Marcela V. Maus

Blood (2021) 138 (Supplement 1): 2814.

https://doi.org/10.1182/blood-2021-146927

Published: 2021

Journal Articles

Tisagenlecleucel Demonstrates Safety, Efficacy and CNS Trafficking in Primary CNS Lymphoma

Blood (2021) 138 (Supplement 1): 258.

https://doi.org/10.1182/blood-2021-148444

Published: 2021

Journal Articles

Blocking IFNγ in CAR-T Reduces Checkpoint Inhibitors and Cell-Mediated Toxicity without Compromising Therapeutic Efficacy in CD19 + malignancies

Stefanie R. Bailey, Sonika Vatsa, Rebecca Larson, Amanda A Bouffard, Irene Scarfò, Kathleen M.E. Gallagher, Matthew J. Frigault, Marcela V. Maus

Blood (2021) 138 (Supplement 1): 1723.

https://doi.org/10.1182/blood-2021-146042

Published: 2021

Journal Articles

Association of Bridging Therapy Utilization with Clinical Outcomes in Patients Receiving Chimeric Antigen Receptor (CAR) T-Cell Therapy

P. Connor Johnson, Caron Jacobson, Alisha Yi, Areej El-Jawahri, Matthew J. Frigault

Blood (2021) 138 (Supplement 1): 4100.

https://doi.org/10.1182/blood-2021-152479

Published: 2021

Journal Articles

Phase 1 Study of CD37-Directed CAR T Cells in Patients with Relapsed or Refractory CD37+ Hematologic Malignancies

Matthew J. Frigault, Yi-Bin Chen, Kathleen M.E. Gallagher, Nora K. Horick, Areej El-Jawahri, Irene Scarfò, Marc Wehrli, Lu Huang, Keagan Casey, Daniella Cook, Thomas Spitzer, Steven McAfee, Frederic I. Preffer, Myriam Armant, Kit L. Shaw, Heather Daley, Sarah Nikiforow, Jerome Ritz, Marcela V. Maus

Blood (2021) 138 (Supplement 1): 653.

https://doi.org/10.1182/blood-2021-146236

Published: 2021

NARROW

Phase 1 study of CAR-37 T cells in patients with relapsed or refractory CD37 + lymphoid malignancies

Two years later: CD19 CAR-T going the distance

Itacitinib for the Prevention of Immune Effector Cell Therapy-Associated Cytokine Release Syndrome: Results from the Phase 2 Incb 39110-211 Placebo-Controlled Randomized Cohort

Real-World Tisagenlecleucel Outcomes in Richter-Transformed Chronic Lymphocytic Leukemia: A Center for International Blood & Marrow Transplant Research (CIBMTR) Analysis

Phase 1 Study of CART-Ddbcma for the Treatment of Patients with Relapsed and/or Refractory Multiple Myeloma: Results from at Least 1-Year Follow-up in All Patients

Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Secondary Central Nervous System Large B-Cell Lymphoma (SCNSL): A Multicenter Retrospective Analysis

Durable Efficacy and Manageable Safety in Patients Age ≥ 75 Years with Relapsed/Refractory Large B-Cell Lymphoma Treated with Tisagenlecleucel in the Real-World Setting

Trial-in-Progress: A Phase 1/2 Multi-Center Study of Onct-808, a ROR1-Specific CAR T, in Adult Patients with Relapsed/Refractory Aggressive B Cell Lymphoma

Use of Cilta-Cel CAR T Cells Following Previous Use of a BCMA-Directed CAR T-Cell Product in Heavily Treated Patients with Relapsed/Refractory Multiple Myeloma: A Single Institution Case Series

Chemotherapy-induced reversal of ciltacabtagene autoleucel–associated movement and neurocognitive toxicity

Neurologic toxicities following adoptive immunotherapy with BCMA-directed CAR T cells

Clonal hematopoiesis of indeterminate potential and risk of death from COVID-19

Safety and efficacy of tisagenlecleucel in primary CNS lymphoma: a phase 1/2 clinical trial

Real-World Efficacy and Safety Outcomes for Patients with Relapsed or Refractory (R/R) Aggressive B-Cell Non-Hodgkin's Lymphoma (aBNHL) Treated with Commercial Tisagenlecleucel: Update from the Center for International Blood and Marrow Transplant Research (CIBMTR) Registry

Rational Chemical and Genetic Modifications Enhance Avidity and Function of CD70-Directed CAR-T-Cells for Myeloid Leukemia

A Phase II Trial of Anakinra for the Prevention of CAR-T Cell Mediated Neurotoxicity

Tisagenlecleucel Demonstrates Safety, Efficacy and CNS Trafficking in Primary CNS Lymphoma

Blocking IFNγ in CAR-T Reduces Checkpoint Inhibitors and Cell-Mediated Toxicity without Compromising Therapeutic Efficacy in CD19 + malignancies

Association of Bridging Therapy Utilization with Clinical Outcomes in Patients Receiving Chimeric Antigen Receptor (CAR) T-Cell Therapy

Phase 1 Study of CD37-Directed CAR T Cells in Patients with Relapsed or Refractory CD37+ Hematologic Malignancies

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only